Your Investor Presentation

w/ SMSbiotech Advisor Ken Berenger

In this video:

Discover how SMSbiotech’s breakthrough stem cell platform could redefine modern medicine.

Learn how one stem cell innovation could unlock hundreds of billion-dollar treatments for diseases once thought untreatable.

See why early investors are getting in on a clinical-stage biotech already years ahead of the pack and poised for massive growth.

Learn how YOU can invest in science that heals, restores, and gives hope where none existed.

Offering Details

Offering Details

Valuation I $191M

Share Price | $28.13

Round Size | $15.75M

Min Investment| $10K

Eligibility | Accredited Investors

Take Your Next Step

Take Your Next Step

VALUATION

SHARE PRICE

ROUND SIZE

MINIMUM INVESTMENT

ELIGIBILITY

$191M

$28.13

$15.75M

$10,000

ACCREDITED INVESTORS

Investor Materials

Review the investment offering

and company details.

Review the slides shared in the investor presentation video

Press Release - Phase 1 Clinical Trials get the Green Light

Press Release - Cooperative Research & Development Agreement signed with U.S. Army

DISCLAIMER

The securities referred to in this website may be sold only to accredited investors, which for natural persons, are investors who meet certain minimum annual income or net worth thresholds. These securities are being offered in reliance on an exemption from the registration requirements of the Securities Act and are not required to comply with specific disclosure requirements that apply to registration under the Securities Act. The Securities and Exchange Commission has not passed on the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials. The securities are subject to legal restrictions on transfer and resale and investors should not assume that they will be able to resell their securities. Investing in securities involves risk, and investors should be able to bear the loss of their investment.

SAFE HARBOR STATEMENT

Matters discussed in this website contain forward-looking statements. When used in this update, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with our history of losses and our need to raise additional financing, the acceptance of our products and technology in the marketplace, our ability to demonstrate the commercial viability of our products and technology and our need to increase the size of our organization. Further information on the Company's risk factors is contained in the Company's quarterly and annual reports as filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason except as may be required under applicable law.

Copyright © SMSbiotech 2025. All Rights Reserved.